Compare CAL & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | SCTX |
|---|---|---|
| Founded | 1878 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 536.5M |
| IPO Year | 1994 | 2026 |
| Metric | CAL | SCTX |
|---|---|---|
| Price | $12.77 | $28.06 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 543.6K | 220.5K |
| Earning Date | 05-28-2026 | N/A |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $85,513,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $2.45 | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | ★ 0.46 | N/A |
| 52 Week Low | $8.80 | $17.31 |
| 52 Week High | $15.04 | $39.60 |
| Indicator | CAL | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 49.37 |
| Support Level | $11.61 | $27.41 |
| Resistance Level | $14.06 | $39.60 |
| Average True Range (ATR) | 0.69 | 3.41 |
| MACD | 0.01 | -0.40 |
| Stochastic Oscillator | 44.36 | 34.66 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.